

# ASCIA AGM 2022

Chair: Professor Michaela Lucas  
ASCIA President

## AGENDA

- Acceptance of AGM 2021 Minutes
- ASCIA President's Report
- ASCIA Finance Report
- ASCIA Council Nominations
- Incoming President's Address



# ASCIA President's Report

## Professor Michaela Lucas

---

### **On behalf of ASCIA:**

- Welcome to the ASCIA Annual General Meeting 2022
- I wish to acknowledge the traditional custodians of the land and sea in which we all live and work
- Congratulations and thank you to Dr Dean Tey and his committee
- Thank you to the ASCIA and ICMSA teams for their organisation of the conference




# ASCIA Membership

There was a total of **730** ASCIA members as of 30 June 2022

This represents a 2.6 fold increase over the past 15 years since 2007, when there were 280 ASCIA members.

ASCIA membership (cumulative)




# ASCIA Membership

Membership comprises:

- Full - 37%
- Associate Medical – 19%
- Associate Nurse – 17%
- Associate Trainee – 10%
- Associate Dietitian – 7%
- Associate Scientist – 6%
- Retired – 3%
- Associate Other – 1%

## ASCIA Membership Categories 30 June 2022



# ASCIA Highlights 2021-2022

---

## **ASCIA CONFERENCE**

- Leading source of allergy and clinical immunology CPD in Australia and New Zealand
- ASCIA 2021 Conference - highly successful virtual event – 694 delegate registrations
- ASCIA 2022 Conference - first hybrid ASCIA Conference – 552 delegate registrations (60% in-person)



# ASCIA Highlights 2021-2022


---

## ASCIA WEBSITE

ASCIA provides world leading, accessible, consistent and evidence-based online resources, education and training.

From 1 July 2021 to 30 June 2022 the ASCIA website attracted more than:

- 3.2 million pageviews
- 2.1 million visits
- 1.7 million unique visitors



# ASCIA Highlights 2021-2022

---

## ASCIA E-TRAINING COURSES

ASCIA has provided world leading online training since 2010, with more than:

- 110,950 registrations from 1 July 2021 to 30 June 2022
- 898,000 registrations since March 2010



# ASCIA Highlights 2021-2022

---

## **ASCIA ANAPHYLAXIS E-TRAINING**

- Significant updates to all ASCIA anaphylaxis e-training courses for health professionals, schools, childcare and community
- Two new anaphylaxis refresher courses developed
- State specific courses updated for NSW, VIC, QLD and WA schools





# ASCIA Highlights 2021-2022

---

## **ASCIA ALLERGY E-TRAINING COURSES**

The following courses for health professionals have been updated in 2022:

- Food Allergy
- Allergen Immunotherapy
- Allergic Rhinitis




# ASCIA Highlights 2021-2022

---

## **ASCIA IMMUNODEFICIENCY E-TRAINING**

- New ASCIA IRT e-training for health professionals
- Developed in 2022 by ASCIA in conjunction with the National Prescribing Service (NPS) MedicineWise Value in Prescribing (ViP) Immunoglobulin (Ig) Project



# ASCIA Highlights 2021-2022

---

## **ASCIA COMMUNICATION**

New format of ASCIA e-newsletters has been introduced in 2022 to enhance the user experience.

Each month ASCIA e-newsletters are sent to:

- >700 ASCIA members
- >5,000 community subscribers



# ASCIA Highlights 2021-2022

---

## **ADVOCACY AND COLLABORATIONS**

- ASCIA lodged 15 submissions from 1st July 2021 to 30th June 2022
- ASCIA collaborates with over 30 groups
- ASCIA collaborations include the National Allergy Council (NAC) and TAPID
- Government funding confirmed for NAC and National Allergy Centre of Excellence (NACE) from 2022-2026



# ASCIA Highlights 2021-2022

---

## AIFA RESEARCH GRANTS

- A total of \$629,000 awarded to 27 research projects since 2015
- The 18 research projects that received AIFA grants up to 2020 have been presented at ASCIA Conferences
- Thank you to our generous donors, sponsors and grant selection panel



# ASCIA Highlights 2021-2022

---

## **ASCIA IMMUNODEFICIENCY STRATEGY**

- Launched on World Immunology Day, 29 April and World HAE Day, 16 May 2022
- Extensive media coverage
- SCID NBS government announcements since launch
- Implementation of Strategy is a priority for ASCIA in 2022-2023



# ASCIA Highlights 2021-2022

---

## **ASCIA SUSTAINABILITY**

- ASCIA has continued to improve its sustainability, both environmentally and financially
- Changing the format of ASCIA Conferences to Virtual in 2021 and Hybrid in 2022 demonstrates that ASCIA can adapt its operations in response to challenges



# ASCIA Highlights 2021-2022

---

## **ADVANCED TRAINING MEETING**

- ASCIA hosted an in-person Advanced Training Meeting on 18 June 2022
- Allergy, immunodeficiency and autoimmunity cases were presented
- It has not been feasible to host training meetings for the past 2 ½ years
- It is our intention to host ASCIA Advanced Training Meetings in 2023 and 2024





# ASCIA Priorities 2022-2023

---

ASCIA has reviewed priorities for 2022-2023, which are grouped into three areas:

- **Member Services**
- **Professional Development**
- **Collaborations**

There are considerable synergies and overlap between these priority areas.



[www.allergy.org.nz](http://www.allergy.org.nz)

ASCIA is the national body for allergy and immunology in New Zealand

# ASCIA Priorities 2022-2023

---

There are considerable synergies and overlap between these priority areas and this report focuses on the priorities that are highlighted below:

## **ASCIA Member Services**

- Communications
- Website
- AIFA Research Grants
- Sustainability
- Advocacy and Submissions

## **ASCIA Professional Development**

- ASCIA Annual Conference
- ASCIA Committees and Working Parties
- ASCIA Online Resources, Education and Training

## **ASCIA Collaborations**

- National Allergy Strategy
- Collaborations with Research Groups
- Professional and Patient Organisations
- ASCIA Immunodeficiency Strategy

# ASCIA Website Health Professionals

---

**New webpages for health professionals have been developed** to enhance the user experience and improve access to ASCIA website:

- Resources
- Allergy and anaphylaxis e-training
- Immunodeficiency e-training
- Pharmacist e-training



# ASCIA Website Patients and Carers

---

**New webpages for patients and carers have been developed** to enhance the user experience and improve access to ASCIA website information.

**ReadSpeaker** has been added, to allow translations and improve access for people with vision impairment, limited reading ability, or learning disabilities, by allowing text to speech (TTS).



# ASCIA 2023 Conference

---

## **Chair: Dr Katie Frith**

- Hybrid event - Tuesday 5th to Friday 8th September
- In-person participation - International Convention Centre, Sydney



# ASCIA 2024 Conference

---

**Chairs: Dr Tiffany Hughes, Dr Jovanka King**

- Hybrid event - Tuesday 3rd to Friday 6th September
- In-person participation – Adelaide Convention Centre



# Implementation of Immunodeficiency Strategy

---

The ASCIA Immunodeficiency Strategy for Australia and New Zealand has been developed in consultation with patient organisations and other stakeholders.

The Strategy was launched in April and May 2022, and implementation will be a priority for ASCIA in 2022-2023.



# Expansion of the National Allergy Strategy

---

Implementation of the National Allergy Strategy will continue by the new:

- **National Allergy Council (NAC)**
- **National Allergy Centre of Excellence (NACE)**

The NAC and NACE are backed by a \$26.9 million Federal Government investment, in response to a Parliamentary Inquiry report.





# National Allergy Council

---

- The **National Allergy Council (NAC)** is a natural progression of the highly valued and successful National Allergy Strategy.
- The NAC will continue to implement and expand the National Allergy Strategy as a partnership between **the Australasian Society of Clinical Immunology and Allergy (ASCI)** and **Allergy & Anaphylaxis Australia (A&AA)** – the leading medical and patient support organisations for allergy in Australia.

**national  
allergy  
council**



# National Allergy Centre of Excellence

---

- The Centre for Food & Allergy Research (CFAR), hosted at the Murdoch Children's Research Institute, will work alongside the new **National Allergy Centre of Excellence (NACE)**.
- As Australia's peak allergy research body, it will develop hubs for allergy research, repository and discovery, evidence and translation, and training and innovation.
- This will ensure Australia remains at the forefront of evidence-based management of allergic disease.



# NAC and NACE working together

---

- The NAC and NACE, with support from the ASCIA and A&AA, encompassing clinicians, researchers, policy-makers, patients and carers, look forward to working together to ensure efficient translation of the latest research into practice.
- These initiatives will help accelerate allergy research and clinical care, to improve the lives of five million Australians living with allergic disease and prevent anaphylaxis, including needless deaths.

**national allergy council**



# ASCIA President's Report

---

It is a very exciting time for allergy and clinical immunology.

ASCIA is at the forefront to lead initiatives in Australia and New Zealand to improve access and standards of care for patients with allergies, immunodeficiencies and other immune system disorders.



# ASCIA President's Report

## Professor Michaela Lucas

---

I take this opportunity to thank:

- ASCIA staff - Jill Smith, Rikki Dunstall, Michelle Haskard, Nadene Dorling, Sandra Vale (NAS) and Heather Roberts (NAS)
- ASCIA contractors - Impagination (ASCIA e-training and websites), ICMSA (ASCIA Conference) and Rachael Hopkins (graphic design)
- ASCIA Directors – Theresa Cole, Michael O’Sullivan, Jane Peake, and ASCIA Council members
- Past ASCIA Presidents who established a strong foundation for ASCIA
- All ASCIA members, many of whom are active members of ASCIA committees and working parties

# ASCIA Finance Report

## Dr Michael O'Sullivan

---

This report is based on the audited ASCIA financial report which covers the 2022 financial year (FY22) from 1<sup>st</sup> July 2021 to 30<sup>th</sup> June 2022.

ASCIA's financial report is consolidated to include ASCIA, AIFA and the National Allergy Strategy (NAS), held in separate bank accounts.

The consolidated profit of \$287,306 for the FY22 is largely due to the highly successful ASCIA 2021 Virtual Conference.




# ASCIA Finance Report

Despite significant growth and challenges, ASCIA has retained its earnings over the past 9 years.

Decreased assets in FY19 and FY20 reflect:

- ASCIA office purchase in 2019
- No ASCIA 2020 Conference due to the COVID-19 pandemic

**ASCIA Financial Position FY14-FY22**




# ASCIA Finance Report

ASCIA's cash at bank reflects:

- Steady growth from FY14 to FY18
- ASCIA office purchase in FY19 and no ASCIA 2020 Conference
- A steady increase in FY21-FY22.

## ASCIA Cash at Bank FY14-FY22






# ASCIA Finance Report

Whilst ASCIA is a not for profit organisation, it is important that the ASCIA Annual Conference results in a profit, to ensure sustainability for ASCIA.

It is a requirement that all NAS govt funds are spent in the same FY as they are provided.

The intention of AIFA is to breakeven each year, to ensure that all donations to AIFA fund research.

## ASCIA, NAS, AIFA P&L FY22



# ASCIA Finance Report

---

ASCIA has continued to improve its financial sustainability:

- ASCIA has no debt, a considerable fixed asset (ASCIA Office) and cash flow
- Changing ASCIA Conferences to Virtual and Hybrid has had many positive effects including financial benefits
- Government funding for National Allergy Strategy projects via the new National Allergy Council over the next four years will provide an additional stable income source for ASCIA



# ASCIA Finance Report

---

The financial outlook for ASCIA in 2022-2023 is very positive, due largely to ASCIA's sound financial position, which reflects:

- Strategic planning
- Monitoring of finances
- Revised focus on ASCIA priorities to balance funded and unfunded work
- Successful new format for the ASCIA Annual Conferences
- Successful advocacy for expansion of the National Allergy Strategy



# ASCIA Council Nominations

## Prof Michaela Lucas

---

The following nominations for Council positions have been received so no elections are required for those positions.

**ASCIA President:** A/Prof Theresa Cole (VIC) – currently ASCIA President Elect

**ASCIA President Elect:** Dr Michael O’Sullivan (WA) – currently ASCIA Director

Nominated by: Prof Michaela Lucas

Seconded by: Prof Dominic Mallon

**ASCIA Director:** Dr Kathryn Patchett (NSW) – outgoing Education Committee Chair

Nominated by: A/Prof Jane Peake

Seconded by: Dr Michael O’Sullivan

# ASCIA Council Nominations

## Prof Michaela Lucas

---

**ASCIA Education Committee Chair:** Dr Joseph De Luca (VIC)

Nominated by: Dr Jack Godsell

Seconded by: Dr Samantha Chan

**ASCIA Immunodeficiency Committee Chair:** Dr Patrick Quinn (SA) – currently Deputy Chair

Nominated by: A/Prof Theresa Cole

Seconded by: A/Prof Jane Peake

**ASCIA Drug Allergy Committee Chair:** Dr James Yun (NSW) – currently Deputy Chair

Nominated by: Prof Connie Katelaris AM

Seconded by: Prof Michaela Lucas

A nomination has not yet been received for the role of ASCIA NSW Representative.

# ASCIA Council Nominations

Prof Michaela Lucas

---

Congratulations and welcome to the new ASCIA Council members: Dr Joseph De Luca, Dr Patrick Quinn and Dr James Yun.

I also take this opportunity to thank the outgoing ASCIA Council members: Prof Connie Katelaris AM, and Dr Brynn Wainstein, for their tremendous contributions, which will be greatly missed.

However, it is reassuring to know that they will still be involved in many ASCIA initiatives.

# ASCIA President's Report

## Professor Michaela Lucas

---

I am honoured and proud to have been the ASCIA President over the past two years.

Despite challenges, ASCIA has continued to grow even stronger, as a world leading, innovative and active professional society.

It has been a pleasure to see you at the 32<sup>nd</sup> ASCIA Conference in Melbourne and I look forward to seeing you in Sydney next September.

I now handover to the new ASCIA President, Dr Theresa Cole.



# Incoming ASCIA President's message

---

Dr Theresa Cole



australasian society of clinical immunology and allergy





# ASCIA 2022 Closing Function

---



australasian society of clinical immunology and allergy

